Eli Lilly has ... cancer drug from privately held Scorpion Therapeutics for as much as $2.5 billion. As part of the deal, Scorpion will spin out a new, independent company that will hold its ...

Lilly's stock went on a tear in the beginning of 2023, with the company's shares doubling as investors bet on the drug's popularity. The stock stumbled in October last year, after Zepbound's sales ...

Eli Lilly and Co., which cemented ... The Boston biotech is going to spin out a new company to hold its employees and develop its non-PI3Kα pipeline drugs. The new company will be independent ...